Acomplia

European Medicines Agency ( EMEA ) has completed a review of Rimonabant ( Acomplia ) after concerns about its psychiatric...


European Medicines Agency ( EMEA ) has completed a review of Rimonabant ( Acomplia ) after concerns about its psychiatric...


The EMEA ( European Medicines Agency ) has recommended contraindicating Acomplia ( Rimonabant ), in patients with ongoing major depression...


Rimonabant ( Acomplia / Zimulti ) is a cannabinoid receptor antagonist. It acts by blocking a specific type of receptor...


Patients taking anti-obesity drugs will only see modest weight loss and many will remain significantly obese or overweight. The study, which...


Patients given Rimonabant are at increased risk of severe psychiatric events. The prevalence of obesity continues to increase worldwide, and there...


Acomplia ( Rimonabant ), a CB1 cannabinoid receptor antagonist, was approved by EMEA ( European Medicines Agency ) for the...


Marijuana, or more specifically its active ingredient, tetrahydrocannabinol, has a well-documented tendency to stimulate hunger. And while researchers have traced...


Use of the weight-loss medication Rimonabant ( Acomplia ) produced modest yet sustained weight loss after 2 years, and improved...


Rimonabant ( Acomplia ) has demonstrated that it can lower blood glucose and reduce weight and waist circumference, as well...